{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349182","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2026-08-13T20:10:16+00:00","discovered_at":"2026-08-13T20:12:10.238677+00:00","generated_at":"2026-08-13T20:12:38.459625+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium Q2 2026 net loss $4.7M; cash $57.2M funds operations into 2029","bullets":["Net loss $4.7M ($0.04/share) vs $5.7M ($0.16/share) in Q2 2025; R&D spend down to $2.8M from $4.1M.","Cash and equivalents $57.2M at June 30, 2026, down from $61.3M at March 31, 2026; runway into 2029.","EQ504 Phase 1 proof-of-mechanism study expected to start Q4 2026; topline data ~6 months later.","IND-enabling work initiated for inhaled EQ504 (lung disease) and oral EQ302 (celiac disease).","Clinical Advisory Board for EQ504 ulcerative colitis program chaired by Prof. Bruce Sands (Mount Sinai)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349182","json":"https://secwatch.observer/filing/0001193125-26-349182.json","markdown":"https://secwatch.observer/filing/0001193125-26-349182.md","text":"https://secwatch.observer/filing/0001193125-26-349182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/0001193125-26-349182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:12:38.459625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}